PortfoliosLab logoPortfoliosLab logo

Documentation

Upgrade your plan

KraneShares MSCI All China Health Care Index UCITS ETF USD (KURE.L) Sharpe Ratio: -0.33

ETF · Currency in USD · Last updated Jun 5, 2026

KURE.L is a passive ETF by MLC Management tracking the investment results of the MSCI World/Health Care NR USD. KURE.L launched on Jan 14, 2021 and has a 0.65% expense ratio.

KURE.L's Sharpe Ratio of -0.33 indicates that for each unit of volatility, it generates -0.33 units of excess return above the risk-free rate. The ratio is calculated using historical daily returns over the past 12 months (as of Jun 5, 2026).

Sharpe uses total volatility (standard deviation) which includes both upside and downside price movements, making it useful for comparing risk-adjusted returns across different assets.

KURE.L Sharpe Ratio Rank

KURE.L Sharpe Ratio Rank: 6.16
Concerning

KURE.L ranks above 6.1% of all investments in our database based on Sharpe Ratio over the past 12 months, indicating weak returns relative to total risk taken. Securities are ranked from 0 (worst) to 100 (best).

What moves the rank

  • Strong returns with low total volatility → Higher rank
  • High volatility (both upside and downside) → Lower rank
  • Consistent returns → Higher rank than volatile returns of same magnitude
  • Sharp drawdowns increase volatility → Lower rank

What you can do with this information

  • Weak risk-adjusted returns relative to category peers
  • Evaluate whether this holding aligns with your risk-return objectives
  • Consider reducing exposure or re-evaluating position size
  • Review higher-ranked alternatives in the same category

KURE.L Sharpe Ratio Market Positioning

The chart shows KURE.L's Sharpe Ratio relative to all ETFs on our platform, with color zones indicating percentile rankings. Higher ratios indicate better risk-adjusted returns.

  • Red zone (bottom 25%): 0.86 or lower
  • Yellow zone (middle 50%): 0.86 to 2.39
  • Green zone (top 25%): 2.39 or higher
  • Top 1%: 7.70+
  • Median: 1.69 — half of all investments score higher

How it compares to other similar ETFs

The table compares KraneShares MSCI All China Health Care Index UCITS ETF USD's Sharpe Ratio with other ETFs in the Health & Biotech Equities category across multiple time periods, showing how KURE.L's risk-adjusted performance compares to similar funds.

Data shows 1-, 5-, and 10-year periods, plus each fund's all-time average, as of Jun 5, 2026.

SymbolName1Y Sharpe Ratio5Y Sharpe Ratio10Y Sharpe RatioAll Time Sharpe Ratio
BTEK.LiShares Nasdaq US Biotechnology UCITS ETF2.24
GNOG.LGlobal X Genomics & Biotechnology UCITS ETF2.16
BTEE.LiShares Nasdaq US Biotechnology UCITS ETF USD (Dist)2.10
SBIO.LInvesco Nasdaq Biotech UCITS ETF2.09
FBT.LFirst Trust NYSE Arca Biotechnology UCITS ETF Acc1.92
WBIO.LWisdomTree BioRevolution UCITS ETF USD Acc1.91
DOCG.LL&G Healthcare Breakthrough UCITS ETF1.62
DOCT.LL&G Healthcare Breakthrough UCITS ETF1.48
XGES.LXtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C1.45
DRDR.LiShares Healthcare Innovation UCITS ETF USD (Acc)1.39
KURE.LKraneShares MSCI All China Health Care Index UCITS ETF USD-0.33

S&P 500 Index

How to choose period

Historical Sharpe Ratio

The chart shows KURE.L's rolling Sharpe ratio over time compared to your chosen benchmark. Rising trends indicate improving returns relative to total volatility, while declining trends may signal deteriorating risk-adjusted performance or increased volatility. Use multiple timeframes to distinguish short-term fluctuations from long-term patterns.

Identify market cycles by observing when KURE.L consistently outperforms (line above benchmark), underperforms (below benchmark), or aligns with the benchmark.

Loading charts...

Sharpe Ratio Calculator

How does KURE.L fit in your portfolio?

Add your other holdings to see your portfolio's Sharpe Ratio and find out.

Analyze Your Portfolio